Thompson Davis & CO. Inc. Has $1.62 Million Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)

Thompson Davis & CO. Inc. increased its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 44.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,130 shares of the company's stock after purchasing an additional 6,530 shares during the quarter. GeneDx accounts for 1.0% of Thompson Davis & CO. Inc.'s holdings, making the stock its 8th biggest position. Thompson Davis & CO. Inc. owned about 0.08% of GeneDx worth $1,624,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. CWM LLC acquired a new stake in shares of GeneDx during the third quarter worth $89,000. Raymond James & Associates purchased a new position in GeneDx in the 3rd quarter worth about $8,090,000. Palumbo Wealth Management LLC purchased a new position in GeneDx in the 3rd quarter worth about $287,000. Principal Financial Group Inc. acquired a new stake in GeneDx during the 3rd quarter worth about $604,000. Finally, Chartwell Investment Partners LLC purchased a new stake in GeneDx during the third quarter valued at about $1,722,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction on Monday, December 16th. The shares were sold at an average price of $76.75, for a total value of $286,124.00. Following the completion of the sale, the chief financial officer now owns 28,200 shares of the company's stock, valued at approximately $2,164,350. The trade was a 11.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Katherine Stueland sold 3,661 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $76.37, for a total transaction of $279,590.57. Following the transaction, the chief executive officer now directly owns 62,897 shares in the company, valued at $4,803,443.89. The trade was a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,584 shares of company stock worth $11,336,520 in the last three months. 27.30% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts recently commented on WGS shares. TD Cowen upped their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their target price on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. Wells Fargo & Company lifted their price target on GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, October 30th. Finally, Craig Hallum increased their price objective on GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Stock Up 3.4 %

Shares of NASDAQ:WGS traded up $3.28 during trading on Wednesday, reaching $99.13. 920,800 shares of the company traded hands, compared to its average volume of 1,245,286. The firm has a fifty day simple moving average of $79.67 and a 200 day simple moving average of $64.24. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 1-year low of $7.59 and a 1-year high of $115.60. The firm has a market cap of $2.72 billion, a P/E ratio of -50.58 and a beta of 2.01.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. Analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.